PMID- 34870139 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220428 IS - 2589-9368 (Electronic) IS - 2589-9368 (Linking) VI - 12 DP - 2021 Dec TI - Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver. PG - 100151 LID - 10.1016/j.metop.2021.100151 [doi] LID - 100151 AB - BACKGROUND AND AIMS: Nanoparticles could represent a therapeutic approach for the treatment of various diseases. It has been reported that cerium oxide nanoparticles (CeO(2) NPs) have potential useful effects. Therefore, we aimed to examine the protective effects of the CeO(2) NPs in two models of liver injury, non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride (CCl(4))-induced liver fibrosis, in rats. METHODS: In this experimental study, male rats were randomly divided into different experimental groups including: Experiment 1; group1: healthy rats received normal saline, 2: CCl(4) group, 3: CCl(4) + nanoparticle. Experiment 2; group1: healthy rats received chow diet, 2: NAFLD group, 3: NAFLD + nanoparticle. The oxidative stress markers were determined in the liver and intestine. Tumor necrosis factor-alpha (TNF-alpha) levels were measured by ELISA. Histopathological changes of liver and intestine were evaluated by light microspore. RESULTS: Total antioxidant capacity (TAC) and glutathione (GSH) levels significantly decreased, while malondialdehyde (MDA) and total oxidant status (TOS) were significantly increased in the liver, and intestine of the NAFLD and CCl(4) group compared with control rats. However, the use of nanoparticles significantly normalized these markers. The levels of the TNF-alpha were significantly reduced in the nanoparticle group as compared with NAFLD model and CCl(4)-treated rats. CeO(2) NPs also normalized the liver and intestinal histological changes. CONCLUSIONS: Our finding revealed that CeO(2) NPs has potential protective effects by increasing antioxidant activity, and reducing inflammation. CI - (c) 2021 The Authors. Published by Elsevier Inc. FAU - Abbasi, Ebrahim AU - Abbasi E AD - Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Vafaei, Seyed Alireza AU - Vafaei SA AD - Department of Biology, Islamic Azad University, Sanandaj Branch, Sanandaj, Iran. FAU - Naseri, Nima AU - Naseri N AD - Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Darini, Ali AU - Darini A AD - Department of Nanotechnology, Pharmaceutical Sciences Branch, Islamic Azad University (IAUPS), Tehran, Iran. FAU - Azandaryani, Masoumeh Taheri AU - Azandaryani MT AD - Department of Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Ara, Farhad Kian AU - Ara FK AD - Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. FAU - Mirzaei, Fatemeh AU - Mirzaei F AD - Department of Anatomy, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. LA - eng PT - Journal Article DEP - 20211118 PL - England TA - Metabol Open JT - Metabolism open JID - 101767753 PMC - PMC8626579 OTO - NOTNLM OT - Carbon tetrachloride OT - Cerium oxide nanoparticles OT - Inflammation OT - Liver injury OT - Rats EDAT- 2021/12/07 06:00 MHDA- 2021/12/07 06:01 PMCR- 2021/11/18 CRDT- 2021/12/06 09:27 PHST- 2021/08/31 00:00 [received] PHST- 2021/11/04 00:00 [revised] PHST- 2021/11/05 00:00 [accepted] PHST- 2021/12/06 09:27 [entrez] PHST- 2021/12/07 06:00 [pubmed] PHST- 2021/12/07 06:01 [medline] PHST- 2021/11/18 00:00 [pmc-release] AID - S2589-9368(21)00075-X [pii] AID - 100151 [pii] AID - 10.1016/j.metop.2021.100151 [doi] PST - epublish SO - Metabol Open. 2021 Nov 18;12:100151. doi: 10.1016/j.metop.2021.100151. eCollection 2021 Dec.